Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

Author： Lü Chen   Williams Andrew K   Chalasani Venu   Martínez Carlos H   Chin Joseph  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.11, Iss.1, 2011-01, pp. : 99-108

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sipuleucel-T and immunotherapy in the treatment of prostate cancer

By Dawson Nancy A   Roesch Erin E  

Expert Opinion on Biological Therapy, Vol. 14, Iss. 5, 2014-05 ,pp. : 709-719

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy and immunoprevention of cancer: where do we stand?

By Cavallo Federica   Curcio Claudia   Forni Guido  

Expert Opinion on Biological Therapy, Vol. 5, Iss. 5, 2005-05 ,pp. : 717-726

Informa Healthcare

Access to resources Recommend Favorite

Immunoregulatory T cells in cancer immunotherapy

By Morse Michael A   Clay Timothy M   Mosca Paul   Lyerly H Kim  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 8, 2002-12 ,pp. : 827-834

Informa Healthcare

Access to resources Recommend Favorite

Recent clinical development of dendritic cell-based immunotherapy for prostate cancer

By Rini Brian  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 11, 2004-11 ,pp. : 1729-1734

Informa Healthcare

Access to resources Recommend Favorite

Can we develop biomarkers that predict response of cancer patients to immunotherapy?

By Bonavida B.   Huerta-Yepez S.   Goodglick L.   Mizutani Y.   Miki T.  

Biomarkers, Vol. 10, Iss. 1, 2005-11 ,pp. : 69-76

Informa Healthcare

Access to resources Recommend Favorite